LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

(Image Credits: PIxabay) Novo Nordisk on Wednesday announced that it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors ...

Danish pharmaceutical behemoth Novo ... obesity, both in the U.S." Susannah Streeter, head of money and markets at Hargreaves Lansdown, said the wide range in guidance indicated that Novo Nordisk ...

Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs. The Danish pharmaceutical giant reported turnover from ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy more than ... the drugmaker’s head of U.S. operations and global business development, noting that the GLP-1 med has reached about ...